cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.
Company profile
Ticker
QNCX
Exchange
Website
CEO
Casey Crawford Lynch
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cortexyme, Inc.
SEC CIK
Corporate docs
Subsidiaries
Cortexyme Australia Pty Ltd • Novosteo, LLC • Novosteo Pty Ltd • EryDel US, Inc. • EryDel USA, Inc. • EryDel Italy, Inc. ...
QNCX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
11 Apr 24
S-8
Registration of securities for employees
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
15 Feb 24
8-K
Departure of Directors or Certain Officers
29 Jan 24
8-K/A
Independent Auditors’ Report
5 Jan 24
8-K
Other Events
3 Jan 24
8-K
Termination of a Material Definitive Agreement
22 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Latest ownership filings
4
Rajiv Patni
15 Feb 24
3
Rajiv Patni
15 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
Sofinnova Partners SAS
12 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Charles S. Ryan
2 Feb 24
4
Brendan Hannah
2 Feb 24
4
Dirk Thye
2 Feb 24
4
Dirk Thye
17 Jan 24
SC 13G
Genextra S.p.A.
15 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.63 mm | 21.63 mm | 21.63 mm | 21.63 mm | 21.63 mm | 21.63 mm |
Cash burn (monthly) | 339.33 k | 848.08 k | 2.03 mm | 2.58 mm | 1.61 mm | 1.50 mm |
Cash used (since last report) | 2.30 mm | 5.75 mm | 13.78 mm | 17.50 mm | 10.90 mm | 10.20 mm |
Cash remaining | 19.33 mm | 15.88 mm | 7.85 mm | 4.13 mm | 10.74 mm | 11.43 mm |
Runway (months of cash) | 57.0 | 18.7 | 3.9 | 1.6 | 6.7 | 7.6 |
Institutional ownership, Q3 2023
34.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 9 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 8.03 bn |
Total shares | 14.83 mm |
Total puts | 0.00 |
Total calls | 12.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 3.62 mm | $5.21 mm |
Tang Capital Management | 3.50 mm | $3.92 bn |
Epq LLC, CTYM PS | 1.58 mm | $0.00 |
BML Investment Partners | 1.47 mm | $2.16 mm |
Vanguard | 949.99 k | $1.06 bn |
EPIQ Capital | 926.50 k | $1.04 bn |
PFE Pfizer | 600.00 k | $7.57 mm |
BLK Blackrock | 336.44 k | $376.82 mm |
Renaissance Technologies | 325.00 k | $364.00 k |
Geode Capital Management | 219.60 k | $246.04 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Rajiv Patni | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.3 | 54,000 | 70.20 k | 54,000 |
1 Feb 24 | Charles S. Ryan | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.31 | 145,000 | 189.95 k | 145,000 |
1 Feb 24 | Brendan Hannah | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.31 | 600,000 | 786.00 k | 600,000 |
1 Feb 24 | Dirk Thye | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.31 | 1,500,000 | 1.97 mm | 1,500,000 |